Announcements
- Crossject annonce le vif succès de son augmentation de capital de 8 millions d’euros
- Crossject announces highly successful closing of its €8 million rights offering
- Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
- Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy
- Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en Europe
- Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
- Crossject annonce le lancement d’une augmentation de capital
- Crossject communique ses résultats financiers audités pour 2023
- Crossject reports audited financial results for 2023
- Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
More ▼
Key statistics
On Tuesday, Crossject SA (74C:STU) closed at 1.88, 5.60% above its 52-week low of 1.78, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.96 |
---|---|
High | 2.01 |
Low | 1.88 |
Bid | 1.89 |
Offer | 1.99 |
Previous close | 2.18 |
Average volume | 108.00 |
---|---|
Shares outstanding | 41.09m |
Free float | 31.06m |
P/E (TTM) | -- |
Market cap | 94.91m EUR |
EPS (TTM) | -0.2601 EUR |
Data delayed at least 15 minutes, as of Jun 04 2024.
More ▼